ABOUT DIAMYD MEDICAL
Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development.
We develop two novel disease-modifying drugs: the antigenspecific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapeutic Remygen®.
Diamyd® and Remygen® are evaluated in ongoing clinical studies. The therapies target the underlying causes of diabetes, dysfunction and loss of the pancreas's insulin-producing cells.
Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.